Observational studyDiabetes, obesity & metabolism2026
Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.
Observational study in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.Diabetes, obesity & metabolism · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn December 2022, semaglutide injections for weight management were marketed in Denmark. Pre-marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed. This study aimed to describe real-world use of semaglutide, including dose titration, discontinuation patterns and effectiveness on body weight in adults with overweight or obesity treated in primary care. MATERIALS AND
methodsThis retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark. The primary outcome was the relative mean change in body weight from baseline to 12-months follow-up in individuals who had not discontinued treatment and who had a baseline and a follow-up weight.
resultsA total of 206 individuals were included (76% women; mean age 48 years, standard deviation (SD) 13). Mean baseline body weight was 105 kg (SD 23.8). Twelve months after treatment initiation, 38% (n = 78) had permanently discontinued semaglutide, whilst 15% (n = 30) had temporarily discontinued (paused) semaglutide. Approximately 48% (n = 98) remained on treatment. Amongst these, 40% were treated with ≤ 1.0 mg/week, 30% with 1.7 mg/week and 30% with 2.4 mg/week. Relative mean body weight change after 12 months was -13.6 (95% CI -15.0 to -12.2)%.
conclusionsBased on the experience from utilisation in a single general practise, semaglutide for weight management is frequently discontinued and titrated slower and to lower maintenance doses in real-world clinical practise than in the approved labelling. Despite this, the observed mean weight loss for individuals who had not discontinued treatment was substantial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.